Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer

International Journal of Colorectal Disease

Volumn 21, Issue 6, 2006, Pages 573-581

  Deutscher, Nicole ^a   Bataille, Frauke ^a   Hausmann, Martin ^a   Kiessling, Stephan ^a   Muller Newen, Gerhard ^b   Leeb, Sandra N ^a   Herfarth, Hans ^a   Heinrich, Peter C ^b   Schölmerich, Jürgen ^a   Rogler, Gerhard ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Adenoma; Apoptosis; Colon cancer; Colonic epithelial cells; IL 11R

Indexed keywords

INTERLEUKIN 11 RECEPTOR; RECEPTOR SUBUNIT; STAT3 PROTEIN;

ADULT; AGED; ALPHA CHAIN; ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL ISOLATION; CLINICAL ARTICLE; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; COLON CARCINOMA; COLON MUCOSA; CONTROLLED STUDY; DENSITOMETRY; DOWNSTREAM PROCESSING; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-11 RECEPTOR ALPHA SUBUNIT; INTESTINAL MUCOSA; MALE; MIDDLE AGED; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 33746375044     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-005-0055-8     Document Type: Article

References (40)

1. Du X, Williams DA (1997) Interleukin-11: Review of molecular, cell biology, and clinical use. Blood 89:3897-3908
2. Zhang XG, Gu JJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R (1994) Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 179:1337-1342
3. Muller-Newen G (2003) The cytokine receptor gp130: Faithfully promiscuous. Sci STKE 201:PE40
4. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334:297-314
5. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1-20
6. Nandurkar HH, Hilton DJ, Nathan P, Willson T, Nicola N, Begley CG (1996) The human IL-11 receptor requires gp130 for signalling: Demonstration by molecular cloning of the receptor. Oncogene 12:585-593
7. Cherel M, Sorel M, Apiou F, Lebeau B, Dubois S, Jacques Y, Minvielle S (1996) The human interleukin-11 receptor alpha gene (IL11RA): Genomic organization and chromosome mapping. Genomics 32:49-53
8. Cherel M, Sorel M, Lebeau B, Dubois S, Moreau JF, Bataille R, Minvielle S, Jacques Y (1995) Molecular cloning of two isoforms of a receptor for the human hematopoietic cytokine interleukin-11. Blood 86:2534-2540
9. Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE, Yancopoulos GD (1995) Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267:1349-1353
10. Zhong Z, Wen Z, Darnell JE (1994) Stat3: A STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264:95-98
11. Booth D, Potten CS (2001) Protection against mucosal injury by growth factors and cytokines. J Natl Cancer Inst Monogr 29:16-20
12. Castagliuolo I, Kelly CP, Qiu BS, Nikulasson ST, LaMont JT, Pothoulakis C (1997) IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am J Physiol 273:G333-G341
13. Dickinson EC, Tuncer R, Nadler EP, Koltuksuz U, Boyle P, Alber SM, Watkins SC, Ford HR (2000) Recombinant human interleukin-11 prevents mucosal atrophy and bowel shortening in the defunctionalized intestine. J Pediatr Surg 35:1079-1083
14. Du XX, Doerschuk CM, Orazi A, Williams DA (1994) A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 83:33-37
15. Du X, Liu Q, Yang Z, Orazi A, Rescorla FJ, Grosfeld JL, Williams DA (1997) Protective effects of interleukin- in a murine model of ischemic bowel necrosis. Am J Physiol 272:G545-G552
16. Fiore NF, Ledniczky G, Liu Q, Orazi A, Du X, Williams DA, Grosfeld JL (1998) Comparison of interleukin-11 and epidermal growth factor on residual small intestine after massive small bowel resection. J Pediatr Surg 33:24-29
17. Gibson RJ, Keefe DM, Thompson FM, Clarke JM, Goland GJ, Cummins AG (2002) Effect of interleukin-11 on ameliorating intestinal damage after methotrexate treatment of breast cancer in rats. Dig Dis Sci 47:2751-2757
18. Keith JC Jr, Albert L, Sonis ST, Pfeiffer CJ, Schaub RG (1994) IL-11, a pleiotropic cytokine: Exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells 12(Suppl 1):79-89
19. Kuenzler KA, Pearson PY, Schwartz MZ (2002) IL-11 pretreatment reduces cell death after intestinal ischemia-reperfusion. J Surg Res 108:268-272
20. Liu Q, Du XX, Schindel DT, Yang ZX, Rescorla FJ, Williams DA, Grosfeld JL (1996) Trophic effects of interleukin-11 in rats with experimental short bowel syndrome. J Pediatr Surg 31:1047-1050
21. Orazi A, Du X, Yang Z, Kashai M, Williams DA (1996) Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest 75:33-42
22. Qiu BS, Pfeiffer CJ, Keith JC Jr (1996) Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 41:1625-1630
23. Venkova K, Keith JC Jr, Meerveld BG (2004) Oral treatment with recombinant human interleukin-11 improves mucosal transport in the colon of human leukocyte antigen-b27 transgenic rats. J Pharmacol Exp Ther 308:206-213
24. Peterson RL, Wang L, Albert L, Keith JC Jr, Dorner AJ (1998) Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab Invest 78:1503-1512
25. Peterson RL, Wang L, Albert L, Marchese E, Erickson J, Wong A, Mounts WM, Hayes L, Bouchard P, Keith J (2002) Pharmacogenomic analysis of rhIL-11 treatment in the HLA-B27 rat model of inflammatory bowel disease. Pharmacogenomics J 2:383-399
26. Greenwood-Van Meerveld B, Tyler K, Keith JC Jr (2000) Recombinant human interleukin-11 modulates ion transport and mucosal inflammation in the small intestine and colon. Lab Invest 80:1269-1280
27. Kuenzler KA, Pearson PY, Schwartz MZ (2002) Interleukin-11 enhances intestinal absorptive function after ischemia-reperfusion injury. J Pediatr Surg 37:457-459
28. Sands BE, Bank S, Sninsky CA, Robinson M, Katz S, Singleton JW, Miner PB, Safdi MA, Galandiuk S, Hanauer SB (1999) Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 117:58-64
29. Sands BE, Winston BD, Salzberg B, Safdi M, Barish C, Wruble L, Wilkins R, Shapiro M, Schwertschlag US (2002) Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 16:399-406
30. Kiessling S, Muller-Newen G, Leeb SN, Hausmann M, Rath HC, Strater J, Spottl T, Schlottmann K, Grossmann J, Montero-Julian FA, Scholmerich J, Andus T, Buschauer A, Heinrich PC, Rogler G (2004) Functional expression of the interleukin-11 receptor alpha-chain and evidence of antiapoptotic effects in human colonic epithelial cells. J Biol Chem 279:10304-10315
31. Cantor SB, Elting LS, Hudson DV Jr, Rubenstein EB (2003) Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 97:3099-3106
32. Saitoh M, Taguchi K, Momose K, Suga K, Yamazaki N, Ono C, Suzuki T, Takeuchi O, Yasuda S, Miyata K (2002) Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells. Cancer Chemother Pharmacol 49:161-166
33. Pertusini E, Ratajczak J, Majka M, Vaughn D, Ratajczak MZ, Gewirtz AM (2001) Investigating the platelet-sparing mechanism of paclitaxel/ carboplatin combination chemotherapy. Blood 97:638-644
34. Kurzrock R (2000) rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia. Oncology (Huntingt) 14:9-11
35. Berl T, Schwertschlag U (2000) Preclinical pharmacologic basis for clinical use of rhIL-11 as an effective platelet-support agent. Oncology (Huntingt) 14:12-20
36. Sonis ST, Peterson RL, Edwards LJ, Lucey CA, Wang L, Mason L, Login G, Ymamkawa M, Moses G, Bouchard P (2000) Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol 36:373-381
37. Soda H, Raymond E, Sharma S, Lawrence R, Cerna C, Gomez L, Schaub R, Von Hoff DD, Izbicka E (1999) Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors. Anticancer Drugs 10:97-101
38. Campbell CL, Jiang Z, Savarese DM, Savarese TM (2001) Increased expression of the interleukin-11 receptor and evidence of STAT3 activation in prostate carcinoma. Am J Pathol 158:25-32
39. Zurita AJ, Troncoso P, Cardo-Vila M, Logothetis CJ, Pasqualini R, Arap W (2004) combinatorial screenings in patients: The interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 64:435-439
40. Campbell CL, Guardiani R, Ollari C, Nelson BE, Quesenberry PJ, Savarese TM (2001) Interleukin-11 receptor expression in primary ovarian carcinomas. Gynecol Oncol 80:121-127